Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 615

1.

Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures.

Assassi S, Wang X, Chen G, Goldmuntz E, Keyes-Elstein L, Ying J, Wallace PK, Turner J, Zheng WJ, Pascual V, Varga J, Hinchcliff ME, Bellocchi C, McSweeney P, Furst DE, Nash RA, Crofford LJ, Welch B, Pinckney A, Mayes MD, Sullivan KM.

Ann Rheum Dis. 2019 Aug 7. pii: annrheumdis-2019-215770. doi: 10.1136/annrheumdis-2019-215770. [Epub ahead of print]

PMID:
31391177
2.

Abatacept in Early Diffuse Cutaneous Systemic Sclerosis - Results of a Phase 2 Investigator-Initiated, Multicenter, Double-Blind Randomized Placebo-Controlled Trial.

Khanna D, Spino C, Johnson S, Chung L, Whitfield M, Denton CP, Berrocal V, Franks J, Mehta B, Molitor J, Steen VD, Lafyatis R, Simms RW, Gill A, Kafaja S, Frech TM, Hsu V, Domsic RT, Pope JE, Gordon JK, Mayes MD, Schiopu E, Young A, Sandorfi N, Park J, Hant FN, Bernstein EJ, Chatterjee S, Castelino FV, Ajam A, Wang Y, Wood T, Allanore Y, Matucci-Cerinic M, Distler O, Singer O, Bush E, Fox D, Furst DE.

Arthritis Rheumatol. 2019 Jul 24. doi: 10.1002/art.41055. [Epub ahead of print]

PMID:
31342624
3.

Questioning a publication bias between industry-funded and non-industry-funded randomized controlled trials on biological and small molecule therapy for rheumatoid arthritis.

Cohen N, Lavie RG, Manor Y, Mimouni M, Furst DE, Amarilyo G.

Semin Arthritis Rheum. 2019 Jun 8. pii: S0049-0172(19)30073-3. doi: 10.1016/j.semarthrit.2019.06.006. [Epub ahead of print]

PMID:
31280935
4.

Pneumoproteins KL-6 and CCL-18 Predict Progression of Interstitial Lung Disease in Systemic Sclerosis.

Volkmann ER, Tashkin DP, Kuwana M, Li N, Roth MD, Charles J, Hant FN, Bogatkevich GS, Akter T, Kim G, Goldin J, Khanna D, Clements PJ, Furst DE, Elashoff RM, Silver RM, Assassi S.

Arthritis Rheumatol. 2019 Jun 24. doi: 10.1002/art.41020. [Epub ahead of print]

PMID:
31233287
5.

Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study.

Kwakkenbos L, Thombs BD, Khanna D, Carrier ME, Baron M, Furst DE, Gottesman K, van den Hoogen F, Malcarne VL, Mayes MD, Mouthon L, Nielson WR, Poiraudeau S, Riggs R, Sauvé M, Wigley F, Hudson M, Bartlett SJ.

Rheumatology (Oxford). 2019 Jun 5. pii: kez234. doi: 10.1093/rheumatology/kez234. [Epub ahead of print] No abstract available.

PMID:
31168593
6.

Targeting inflammatory pathways in axial spondyloarthritis.

Furst DE, Louie JS.

Arthritis Res Ther. 2019 Jun 4;21(1):135. doi: 10.1186/s13075-019-1885-z. Review.

7.

Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials.

Klokker L, Berthelsen DB, Woodworth T, Andersen KM, Furst DE, Devoe D, Williamson PR, Suarez-Almazor ME, Strand V, Leong AL, Goel N, Boers M, Brooks PM, March L, Sloan VS, Tugwell P, Simon LS, Christensen R.

J Rheumatol. 2019 May 1. pii: jrheum.190196. doi: 10.3899/jrheum.190196. [Epub ahead of print]

PMID:
31043547
8.

Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study.

Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Maldonado MA, Huizinga TW.

RMD Open. 2019 Feb 8;5(1):e000840. doi: 10.1136/rmdopen-2018-000840. eCollection 2019.

9.

Study of MRI brain findings and carotid US features in systemic sclerosis patients, relationship with disease parameters.

Gamal RM, Abozaid HSM, Zidan M, Abdelmegid MAF, Abdel-Razek MR, Alsayed SA, Mourad AF, Azoz NMA, Mohram LA, Furst DE.

Arthritis Res Ther. 2019 Apr 15;21(1):95. doi: 10.1186/s13075-019-1877-z.

10.

Timely renal transplantation for scleroderma end-stage kidney disease patients can improve outcomes and quality of life.

Woodworth TG, Furst DE.

Ann Transl Med. 2019 Feb;7(3):60. doi: 10.21037/atm.2018.12.64. No abstract available.

11.

Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II.

Volkmann ER, Tashkin DP, Sim M, Li N, Khanna D, Roth MD, Clements PJ, Hoffmann-Vold AM, Furst DE, Kim G, Goldin J, Elashoff RM.

J Rheumatol. 2019 Feb 15. pii: jrheum.180441. doi: 10.3899/jrheum.180441. [Epub ahead of print]

PMID:
30770517
12.

Utilize lung ultrasound B-lines and KL-6 to monitor anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis-associated interstitial lung disease: a case report and literature review.

Wang Y, Chen S, Lin Z, Lin J, Xie X, Lin Q, Du G, Huang X, Matucci-Cerinic M, Furst DE.

Clin Rheumatol. 2019 May;38(5):1433-1436. doi: 10.1007/s10067-019-04462-z. Epub 2019 Feb 11. Review.

PMID:
30746580
13.

Genetic and inflammatory factors associated with psoriatic arthritis: Relevance to diagnosis and management.

Furst DE, Belasco J, Louie JS.

Clin Immunol. 2019 May;202:59-75. doi: 10.1016/j.clim.2019.02.001. Epub 2019 Feb 6. Review.

PMID:
30738143
14.

Correction to: On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.

Bykerk VP, Burmester GR, Combe BG, Furst DE, Huizinga TWJ, Ahmad HA, Emery P.

Rheumatol Int. 2019 May;39(5):945. doi: 10.1007/s00296-018-4232-9.

15.

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018.

Winthrop KL, Weinblatt ME, Crow MK, Burmester GR, Mease PJ, So AK, Bykerk V, Van Vollenhoven RF, Dougados M, Kay J, Mariette X, Sieper J, Melchers F, Cronstein BN, Shevach E, Breedfeld FC, Kalden J, Smolen JS, Furst DE.

Ann Rheum Dis. 2019 Jul;78(7):872-878. doi: 10.1136/annrheumdis-2018-214280. Epub 2019 Feb 2. Review.

PMID:
30712015
16.

Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).

Khanna D, Clements PJ, Volkmann ER, Wilhalme H, Tseng CH, Furst DE, Roth MD, Distler O, Tashkin DP.

Arthritis Res Ther. 2019 Jan 16;21(1):23. doi: 10.1186/s13075-019-1809-y.

17.

Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative.

Nielsen SM, Tugwell P, de Wit MPT, Boers M, Beaton DE, Woodworth TG, Escorpizo R, Shea B, Toupin-April K, Guillemin F, Strand V, Singh JA, Kloppenburg M, Furst DE, Wells GA, Smolen JS, Veselý R, Boonen A, Storgaard H, Voshaar M, March L, Christensen R; Contextual Factors Working Group.

J Rheumatol. 2019 Jan 15. pii: jrheum.181081. doi: 10.3899/jrheum.181081. [Epub ahead of print]

PMID:
30647174
18.

Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis.

Curtis JR, Flake DD 2nd, Weinblatt ME, Shadick NA, Østergaard M, Hetland ML, Brahe CH, Hwang YG, Furst DE, Strand V, Etzel CJ, Pappas DA, Wang X, Hwang CC, Sasso EH, Gutin A, Hitraya E, Lanchbury JS.

Rheumatology (Oxford). 2018 Dec 24. doi: 10.1093/rheumatology/key367. [Epub ahead of print]

19.

Preliminary Validation of the Digital Ulcer Clinical Assessment Score in Systemic Sclerosis.

Bruni C, Ngcozana T, Braschi F, Pucci T, Piemonte G, Benelli L, Poli M, Suliman YA, Guiducci S, Bellando-Randone S, Balduzzi S, Grotts J, Denton CP, Rasero L, Montecucco C, Furst DE, Matucci-Cerinic M.

J Rheumatol. 2019 Jun;46(6):603-608. doi: 10.3899/jrheum.171486. Epub 2018 Nov 15.

PMID:
30442833
20.

Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.

Volkmann ER, Tashkin DP, Sim M, Li N, Goldmuntz E, Keyes-Elstein L, Pinckney A, Furst DE, Clements PJ, Khanna D, Steen V, Schraufnagel DE, Arami S, Hsu V, Roth MD, Elashoff RM, Sullivan KM; SLS I and SLS II study groups.

Ann Rheum Dis. 2019 Jan;78(1):122-130. doi: 10.1136/annrheumdis-2018-213708. Epub 2018 Nov 8.

21.

Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and meta-analysis of randomised trials.

Tarp S, Jørgensen TS, Furst DE, Dossing A, Taylor PC, Choy EH, Suarez-Almazor ME, Lyddiatt A, Kristensen LE, Bliddal H, Christensen R.

Semin Arthritis Rheum. 2019 Jun;48(6):958-966. doi: 10.1016/j.semarthrit.2018.10.002. Epub 2018 Oct 9.

PMID:
30396592
22.

Imaging and serum biomarkers in connective tissue disease-associated interstitial lung diseases: correlation between lung ultrasound B-lines and KL-6 levels.

Wang Y, Chen S, Lin Z, Du G, Lin J, Lin Q, Xiufeng H, Zhang G, Furst DE, Gargani L, Matucci-Cerinic M.

Ann Rheum Dis. 2019 Apr;78(4):573-575. doi: 10.1136/annrheumdis-2018-214098. Epub 2018 Oct 23. No abstract available.

PMID:
30352891
23.

On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.

Bykerk VP, Burmester GR, Combe BG, Furst DE, Huizinga TWJ, Ahmad HA, Emery P.

Rheumatol Int. 2018 Dec;38(12):2225-2231. doi: 10.1007/s00296-018-4173-3. Epub 2018 Oct 20. Erratum in: Rheumatol Int. 2019 Feb 5;:.

24.

Telomere dysfunction-related serological markers and oxidative stress markers in rheumatoid arthritis patients: correlation with diseases activity.

Gamal RM, Hammam N, Zakary MM, Abdelaziz MM, Razek MRA, Mohamed MSE, Emad Y, Elnaggar MG, Furst DE.

Clin Rheumatol. 2018 Dec;37(12):3239-3246. doi: 10.1007/s10067-018-4318-5. Epub 2018 Oct 16.

PMID:
30328024
25.

Long-Term Safety of Rituximab in Rheumatoid Arthritis: Analysis From the SUNSTONE Registry.

Winthrop KL, Saag K, Cascino MD, Pei J, John A, Jahreis A, Haselkorn T, Furst DE.

Arthritis Care Res (Hoboken). 2018 Oct 8. doi: 10.1002/acr.23781. [Epub ahead of print]

PMID:
30295434
26.

Vascular Leaking, a Pivotal and Early Pathogenetic Event in Systemic Sclerosis: Should the Door Be Closed?

Bruni C, Frech T, Manetti M, Rossi FW, Furst DE, De Paulis A, Rivellese F, Guiducci S, Matucci-Cerinic M, Bellando-Randone S.

Front Immunol. 2018 Sep 7;9:2045. doi: 10.3389/fimmu.2018.02045. eCollection 2018. Review.

27.

High-frequency ultrasound of the skin in systemic sclerosis: an exploratory study to examine correlation with disease activity and to define the minimally detectable difference.

Li H, Furst DE, Jin H, Sun C, Wang X, Yang L, He J, Wang Y, Liu A.

Arthritis Res Ther. 2018 Aug 16;20(1):181. doi: 10.1186/s13075-018-1686-9.

28.

Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018.

Bartoli F, Bae S, Cometi L, Matucci Cerinic M, Furst DE.

Expert Rev Clin Immunol. 2018 Jul;14(7):539-547. doi: 10.1080/1744666X.2018.1487291. Epub 2018 Jul 4. Review.

PMID:
29925278
29.

Remodeling of the HDL proteome with treatment response to abatacept or adalimumab in the AMPLE trial of patients with rheumatoid arthritis.

Charles-Schoeman C, Gugiu GB, Ge H, Shahbazian A, Lee YY, Wang X, Furst DE, Ranganath VK, Maldonado M, Lee T, Reddy ST.

Atherosclerosis. 2018 Aug;275:107-114. doi: 10.1016/j.atherosclerosis.2018.04.003. Epub 2018 Apr 17.

30.

The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts.

Dougherty DH, Kwakkenbos L, Carrier ME, Salazar G, Assassi S, Baron M, Bartlett SJ, Furst DE, Gottesman K, van den Hoogen F, Malcarne VL, Mouthon L, Nielson WR, Poiraudeau S, Sauvé M, Boire G, Bruns A, Chung L, Denton C, Dunne JV, Fortin P, Frech T, Gill A, Gordon J, Herrick AL, Hinchcliff M, Hudson M, Johnson SR, Jones N, Kafaja S, Larché M, Manning J, Pope J, Spiera R, Steen V, Sutton E, Thorne C, Wilcox P, Thombs BD, Mayes MD; SPIN Investigators.

Rheumatology (Oxford). 2018 Sep 1;57(9):1623-1631. doi: 10.1093/rheumatology/key139.

PMID:
29868924
31.

pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis.

Kafaja S, Valera I, Divekar AA, Saggar R, Abtin F, Furst DE, Khanna D, Singh RR.

JCI Insight. 2018 May 3;3(9). pii: 98380. doi: 10.1172/jci.insight.98380.

32.

Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus.

Ingegnoli F, Schioppo T, Allanore Y, Caporali R, Colaci M, Distler O, Furst DE, Hunzelmann N, Iannone F, Khanna D, Matucci-Cerinic M.

Semin Arthritis Rheum. 2019 Feb;48(4):686-693. doi: 10.1016/j.semarthrit.2018.03.019. Epub 2018 Apr 4.

PMID:
29706243
33.

Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study.

Pappas DA, Nyberg F, Kremer JM, Lampl K, Reed GW, Horne L, Ho M, Onofrei A, Malaviya AN, Rillo OL, Radominski SC, Gal J, Gibofsky A, Popkova TV, Laurindo L, Kerzberg EM, Zahora R, Pons-Estel BA, Curtis JR, Furst DE, Greenberg JD.

Clin Rheumatol. 2018 Sep;37(9):2331-2340. doi: 10.1007/s10067-018-4113-3. Epub 2018 Apr 25.

PMID:
29696436
34.

Autologous Stem-Cell Transplantation for Severe Scleroderma.

Sullivan KM, Goldmuntz EA, Furst DE.

N Engl J Med. 2018 Mar 15;378(11):1066-1067. doi: 10.1056/NEJMc1801275. No abstract available.

PMID:
29539292
35.

Ultrasound characterization of cutaneous ulcers in systemic sclerosis.

Suliman YA, Kafaja S, Fitzgerald J, Wortsman X, Grotts J, Matucci-Cerrinic M, Ranganath VK, Furst DE.

Clin Rheumatol. 2018 Jun;37(6):1555-1561. doi: 10.1007/s10067-018-3986-5. Epub 2018 Mar 10.

PMID:
29525847
36.

Factor structure and convergent validity of the Derriford Appearance Scale-24 using standard scoring versus treating 'not applicable' responses as missing data: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study.

Merz EL, Kwakkenbos L, Carrier ME, Gholizadeh S, Mills SD, Fox RS, Jewett LR, Williamson H, Harcourt D, Assassi S, Furst DE, Gottesman K, Mayes MD, Moss TP, Thombs BD, Malcarne VL; SPIN Investigators.

BMJ Open. 2018 Mar 6;8(3):e018641. doi: 10.1136/bmjopen-2017-018641. Erratum in: BMJ Open. 2018 May 5;8(5):.

37.

A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases.

Rubbert-Roth A, Furst DE, Nebesky JM, Jin A, Berber E.

Rheumatol Ther. 2018 Jun;5(1):21-42. doi: 10.1007/s40744-018-0102-x. Epub 2018 Mar 3. Review.

38.

Reliability and Validity of Three Versions of the Brief Fear of Negative Evaluation Scale in Patients With Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study.

Fox RS, Kwakkenbos L, Carrier ME, Mills SD, Gholizadeh S, Jewett LR, Roesch SC, Merz EL, Assassi S, Furst DE, Gottesman K, Mayes MD, Thombs BD, Malcarne VL; SPIN Investigators.

Arthritis Care Res (Hoboken). 2018 Nov;70(11):1646-1652. doi: 10.1002/acr.23532.

PMID:
29409146
39.

Secular trends in the impact factors of SLE publications over a 45-year period-a systematic review.

Cohen N, Mimouni M, Glatstein MM, Furst DE, Amarilyo G.

Lupus. 2018 Jan 1:961203317751855. doi: 10.1177/0961203317751855. [Epub ahead of print]

PMID:
29320973
40.

Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.

Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, Mayes MD, Nash RA, Crofford LJ, Eggleston B, Castina S, Griffith LM, Goldstein JS, Wallace D, Craciunescu O, Khanna D, Folz RJ, Goldin J, St Clair EW, Seibold JR, Phillips K, Mineishi S, Simms RW, Ballen K, Wener MH, Georges GE, Heimfeld S, Hosing C, Forman S, Kafaja S, Silver RM, Griffing L, Storek J, LeClercq S, Brasington R, Csuka ME, Bredeson C, Keever-Taylor C, Domsic RT, Kahaleh MB, Medsger T, Furst DE; SCOT Study Investigators.

N Engl J Med. 2018 Jan 4;378(1):35-47.

41.

Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations.

Gorlova OY, Li Y, Gorlov I, Ying J, Chen WV, Assassi S, Reveille JD, Arnett FC, Zhou X, Bossini-Castillo L, Lopez-Isac E, Acosta-Herrera M, Gregersen PK, Lee AT, Steen VD, Fessler BJ, Khanna D, Schiopu E, Silver RM, Molitor JA, Furst DE, Kafaja S, Simms RW, Lafyatis RA, Carreira P, Simeon CP, Castellvi I, Beltran E, Ortego N, Amos CI, Martin J, Mayes MD.

PLoS One. 2018 Jan 2;13(1):e0189498. doi: 10.1371/journal.pone.0189498. eCollection 2018.

42.

Scleroderma renal crisis and renal involvement in systemic sclerosis.

Woodworth TG, Suliman YA, Li W, Furst DE, Clements P.

Nat Rev Nephrol. 2018 Feb;14(2):137. doi: 10.1038/nrneph.2017.183. Epub 2018 Jan 2.

PMID:
29292373
43.

A Case Series on Patients on Tofacitinib in Combination With a Biologic.

Barroso NS, Miller EZ, Furst DE.

J Clin Rheumatol. 2018 Sep;24(6):349-351. doi: 10.1097/RHU.0000000000000663. No abstract available.

PMID:
29280829
44.

Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs.

Rigby WFC, Lampl K, Low JM, Furst DE.

Int J Rheumatol. 2017;2017:9614241. doi: 10.1155/2017/9614241. Epub 2017 Oct 31. Review.

45.

Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).

Kafaja S, Clements PJ, Wilhalme H, Tseng CH, Furst DE, Kim GH, Goldin J, Volkmann ER, Roth MD, Tashkin DP, Khanna D.

Am J Respir Crit Care Med. 2018 Mar 1;197(5):644-652. doi: 10.1164/rccm.201709-1845OC. Epub 2017 Nov 3.

46.

Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study.

Hsu VM, Denton CP, Domsic RT, Furst DE, Rischmueller M, Stanislav M, Steen VD, Distler JHW, Korish S, Cooper A, Choi S, Schafer PH, Horan G, Hough DR.

J Rheumatol. 2018 Mar;45(3):405-410. doi: 10.3899/jrheum.161040. Epub 2017 Nov 1.

PMID:
29093152
47.

Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis.

Arnold MB, Khanna D, Denton CP, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Riemekasten G, Steen V, Müller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE, Pope JE.

Rheumatology (Oxford). 2018 Jan 1;57(1):152-157. doi: 10.1093/rheumatology/kex396.

48.

Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).

Khanna D, Denton CP, Lin CJF, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, Müller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE.

Ann Rheum Dis. 2018 Feb;77(2):212-220. doi: 10.1136/annrheumdis-2017-211682. Epub 2017 Oct 24.

49.

Interstitial lung disease points to consider for clinical trials in systemic sclerosis.

Khanna D, Seibold J, Goldin J, Tashkin DP, Furst DE, Wells A.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v27-v32. doi: 10.1093/rheumatology/kex203. Review.

50.

Assessment of skin involvement in systemic sclerosis.

Kumánovics G, Péntek M, Bae S, Opris D, Khanna D, Furst DE, Czirják L.

Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v53-v66. doi: 10.1093/rheumatology/kex202. Review.

Supplemental Content

Loading ...
Support Center